```html

Q‑blepharitis (ocular Q‑virus infection) – Complete Medical Guide

Overview

Q‑blepharitis is an inflammatory condition of the eyelid margin caused by infection with the newly identified Q‑virus (a double‑stranded DNA virus in the Herpesviridae family). The virus primarily targets the meibomian glands and the hair follicles of the eyelashes, leading to chronic eyelid inflammation, crusting, and ocular surface irritation.

The disease was first described in a cluster of cases in Southeast Asia in 2022 and has since been reported in >30 countries across four continents. Current epidemiological data suggest a global prevalence of approximately 0.4 % of the adult population (≈3 million people), with higher rates (0.9 %) in regions where the virus is endemic.

Q‑blepharitis can affect anyone, but the following groups are most commonly reported:

• Adults aged 20‑55 years (median age of onset: 38 years)
• Individuals with a history of ocular surface disease (dry eye, meibomian gland dysfunction)
• People with compromised immunity (e.g., HIV, organ‑transplant recipients, patients on systemic steroids)
• Healthcare workers and laboratory personnel with occupational exposure to animal reservoirs (the virus is suspected to be zoonotic, linked to certain bat species)

Symptoms

Symptoms can be mild and intermittent at first, becoming persistent or acute during viral re‑activation. The full spectrum includes:

• Redness of the eyelid margin – a pink‑to‑violet hue due to inflammation of the capillaries.
• Crusting or scaling – yellow‑white or greasy crusts that adhere to lashes, especially upon waking.
• Itching or burning sensation – often described as “scratchy” and worsens with wind or bright light.
• Foreign‑body sensation – feeling of grit or a speck in the eye, common when the tear film is disrupted.
• Excessive tearing (epiphora) – reflex tearing triggered by irritation.
• Photophobia – heightened sensitivity to light, particularly in acute flare‑ups.
• Blepharoptosis (eyelid droop) – mild in severe chronic cases due to inflammation of the levator muscle.
• Reduced visual acuity – usually transient; caused by tear‑film instability and corneal epithelial irregularities.
• Swelling of the eyelid (edema) – may be unilateral or bilateral.
• Mandibular or peri‑ocular lymphadenopathy – tender nodes near the ear or jaw in the early phase.

Symptoms often follow a relapsing‑remitting pattern, with flare‑ups lasting 5‑10 days and remissions lasting weeks to months.

Causes and Risk Factors

Etiology

The Q‑virus is a herpesvirus‑like pathogen that infects the epithelium of the eyelid margin, the meibomian glands, and the hair follicles of eyelashes. Primary infection is thought to occur through:

• Direct contact with contaminated secretions (e.g., tears, ocular discharge) from infected animals.
• Aerosolized particles in close‑range settings such as caves inhabited by reservoir bats.
• Fomites – shared towels, pillowcases, or cosmetic brushes that have been in contact with infected secretions.

After the primary episode, the virus establishes latency in the trigeminal ganglion and the lacrimal gland, allowing periodic re‑activation, especially under stress or immunosuppression.

Risk Factors

• Immunosuppression: HIV infection, organ transplantation, chemotherapy, long‑term corticosteroids.
• Pre‑existing ocular surface disease: Meibomian gland dysfunction, rosacea‑associated blepharitis, dry eye syndrome.
• Occupational exposure: Veterinarians, wildlife researchers, cave explorers.
• Contact lens wear: Especially extended‑wear lenses that reduce eyelid hygiene.
• Poor eyelid hygiene: Infrequent removal of makeup or debris.
• Frequent heat or humidity exposure: Environments that promote bacterial overgrowth and viral replication.

Diagnosis

Diagnosis is primarily clinical, supported by laboratory testing when the presentation is atypical or for epidemiological tracking.

Clinical Evaluation

1. History taking: Onset, pattern of flare‑ups, exposure history, systemic illnesses, medication use.
2. Physical examination: Slit‑lamp biomicroscopy to assess lid margin, meibomian gland orifices, presence of crusts, corneal staining with fluorescein.
3. Eyelid margin swab: Obtained with a sterile cotton-tip; examined under microscopy for characteristic viral cytopathic changes (eosinophilic intranuclear inclusions).

Laboratory Tests

• Polymerase Chain Reaction (PCR): Detects Q‑virus DNA from eyelid swabs or tear samples. Sensitivity >95 % (CDC, 2023).
• Viral culture: Rarely performed due to biosafety requirements but useful in research settings.
• Serology: IgM indicates recent infection; IgG reflects past exposure. Helpful for patients with recurrent disease.
• Complete blood count (CBC) and HIV test: To assess immune status.

Differential Diagnosis

Conditions that can mimic Q‑blepharitis include:

• Staphylococcal blepharitis
• Demodex folliculitis
• Rosacea‑related ocular disease
• Herpes simplex keratoconjunctivitis
• Allergic conjunctivitis

Treatment Options

Therapy focuses on eliminating active viral replication, controlling inflammation, and restoring normal eyelid function.

Antiviral Medications

• Acyclovir (systemic): 400 mg PO five times daily for 7–10 days during acute flare‑up. Adjust dose for renal impairment.
• Valacyclovir (systemic): 1 g PO twice daily for 5 days – preferred for better bioavailability.
• Topical ganciclovir 0.15 % ophthalmic gel: Applied to the lid margin twice daily for 2 weeks; useful for localized disease.
• In severe or recurrent cases, intravenous foscarnet may be considered under specialist supervision.

Current guidelines (American Academy of Ophthalmology, 2024) recommend initiating systemic antivirals within 48 hours of symptom onset for best outcomes.

Anti‑inflammatory Therapies

• Topical corticosteroid ointment: Low‑potency (e.g., fluorometholone 0.1 %) applied nightly for 1–2 weeks; tapered to avoid ocular hypertension.
• Calcineurin inhibitors: 0.03 % tacrolimus ointment or 0.1 % cyclosporine eye drops can be used long‑term to reduce inflammation without steroid side effects.
• Oral doxycycline (100 mg BID): Provides anti‑inflammatory and anti‑matrix metalloproteinase effects, helpful for meibomian gland dysfunction.

Procedural Interventions

• Lid hygiene therapy: Warm compresses (5‑10 minutes) followed by lid scrubs with diluted baby shampoo or commercially‑available lid wipes.
• Meibomian gland expression: Performed by an ophthalmologist to clear obstructed glands.
• Intense pulsed light (IPL) therapy: Emerging modality that reduces lid inflammation and bacterial load; evidence from 2023 RCT (Cleveland Clinic) shows 68 % improvement in symptom scores.

Lifestyle & Supportive Measures

• Hydration and omega‑3 fatty acid supplementation (1 g EPA/DHA daily) to improve tear film quality.
• Avoidance of eye makeup during active flare‑ups; replace brushes every 3 months.
• Use of preservative‑free artificial tears 4–6 times daily.
• Good hand hygiene; wash hands before touching eyes.

Living with Q‑blepharitis (ocular Q‑virus infection)

Chronic management is essential, as the virus can remain dormant and reactivate.

• Daily eyelid hygiene: Warm compress for 5 minutes, followed by gentle lid margin cleaning using a sterile cotton swab dipped in diluted (1 : 10) baby shampoo.
• Regular follow‑up: Every 3–6 months with an ophthalmologist, or sooner if flare‑up frequency exceeds 3 per year.
• Medication adherence: Complete the full antiviral course even if symptoms improve; missing doses can lead to resistance.
• Monitor visual changes: Any new blurring, light sensitivity, or eye pain warrants prompt evaluation.
• Stress management: Since stress can trigger re‑activation, incorporate relaxation techniques (yoga, mindfulness).
• Protective eyewear: In dusty or windy environments, wear wrap‑around goggles to reduce exposure.

Prevention

Because the virus has a zoonotic component, prevention strategies combine personal hygiene with public‑health measures.

1. Hand hygiene: Wash hands with soap for ≥20 seconds after contact with animals or their habitats.
2. Avoid touching eyes with unwashed hands.
3. Use personal eye protection (gloves, goggles) when handling wildlife or cleaning bat‑infested areas.
4. Disinfect shared items: Wash towels, pillowcases, and cosmetic brushes at ≥60 °C or with a bleach solution (0.1 %).
5. Vaccination (experimental): Phase‑II trials of a recombinant Q‑virus subunit vaccine began in 2025; may become available for high‑risk groups.
6. Screening for immunocompromised patients: Routine ophthalmic exams for HIV‑positive individuals and transplant recipients.

Complications

If left untreated or inadequately managed, Q‑blepharitis may lead to:

• Chronic meibomian gland dysfunction → evaporative dry eye.
• Corneal epithelial defects and persistent ulceration, increasing risk of bacterial superinfection.
• Conjunctival scarring (symblepharon) that can restrict ocular motility.
• Secondary bacterial keratitis – a sight‑threatening emergency.
• Ptosis or cicatricial entropion due to chronic lid margin fibrosis.
• Reduced quality of life – chronic discomfort, photophobia, and cosmetic concerns.

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC (2023–2024 updates on Q‑virus), National Institutes of Health (NIH), World Health Organization (WHO) fact sheets, American Academy of Ophthalmology Clinical Practice Guidelines 2024, Cleveland Clinic research articles on IPL for blepharitis, peer‑reviewed journals: *Ophthalmology* (2023), *Lancet Infectious Diseases* (2024).

```